In a recent study, non-invasive prenatal testing was able to help researchers diagnose fetal anemia earlier during pregnancy.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.